Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUNFLOWER: Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
NCT07430306Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Apr 2026
- Primary completion
- Jan 2029
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 3 trial of anifrolumab in systemic lupus erythematosus (SLE), sponsored by AstraZeneca. Started Apr 2026; status: recruiting.
02
Drugs
anifrolumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT07430306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07430306.